Nasdaq
$3.51▼ 1.40%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $60.3MShares out 17.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 8.18After-hours26.08.19 06:004Ownership#●●●#●●●
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals insider David Zawitz reported a change in beneficial ownership of company securities via SEC Form 4 on August 17, 2026. This filing formalizes the change in the insider's stock holdings, and investors should review the specific details of the equity position adjustment.…more
$3.51-1.40%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.18After-hours26.08.19 06:004Ownership
Verrica Pharmaceuticals Inc.
Insider Noah L. Rosenberg of Verrica Pharmaceuticals Inc. reported a change in beneficial ownership of securities effective August 17, 2026. This filing formalizes the disclosure of insider equity transactions via Form 4.…more
$3.51-1.40%vs prev closeView filingShare - 8.18After-hours26.08.19 06:004Ownership
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals insider Jayson Rieger reported changes in beneficial ownership of securities effective August 14, 2026. This filing serves as a Form 4 statement disclosing the insider's updated equity position.…more
$3.51-1.40%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:00#●●●#●●●
Verrica Pharmaceuticals Secures Full $27.5 Million Non-Dilutive Credit Facility…more
Verrica Pharmaceuticals has achieved operational milestones to unlock the full $27.5 million in non-dilutive credit facility funding. The capital will support the growth of its YCANTH business and the advancement of its Phase 3 clinical programs.…more
$3.51-1.40%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 21:00
●●●●●●●● ●●●●● ●●●●●●
Verrica Pharmaceuticals will present new Phase 3 clinical data for its skin disease treatment YCANTH at upcoming dermatology conferences. While the data highlights faster clearance rates compared to vehicle, the announcement of clinical data presentations is considered a neutral event for the stock.…more
$3.51-1.40%vs prev close - 9.10Pre-market26.09.10 21:05
●●●●●●●● ●●●●● ●●●●●●
Verrica Pharmaceuticals will present new clinical data for its FDA-approved molluscum treatment, YCANTH, and its basal cell carcinoma candidate, VP-315, at upcoming dermatology seminars. These presentations focus on reinforcing the therapeutic efficacy of its product portfolio and the potential of its pipeline.…more
$3.51-1.40%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report